ULTOMIRIS (ravulizumab-cwvz) injection
ULTOMIRIS is a prescription medicine used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Brand name: ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018. FDA approved ravulizumab-cwvz (brand name ULTOMIRIS) is not (yet) registered or available in India but on request Indian patient can buy ULTOMIRIS at the lowest price.
Home | ravulizumab-cwvz injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
ULTOMIRIS (ravulizumab-cwvz) injection
Ravulizumab-cwvz injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). This medicine helps reduce red blood cell destruction or breakdown (hemolysis) in patients with PNH.
ULTOMIRIS is a complement inhibitor indicated for:
• the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
• the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) .
In the United States, ravulizumab is indicated for the treatment of adults and children one month of age and older with paroxysmal nocturnal hemoglobinuria and for the treatment of adults and children one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).[4][6]
In the European Union, ravulizumab is indicated in the treatment of adults with paroxysmal nocturnal haemoglobinuria:
• in people with haemolysis with clinical symptom(s) indicative of high disease activity
• in people who are clinically stable after having been treated with eculizumab for at least the past six months.
Drug (Brand / Generic): ULTOMIRIS / ravulizumab-cwvz
Current Indications: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)
Marketed by:: Alexion Pharmaceuticals, Inc.
Approval Date: 2018
Dosage forms and strengths of ULTOMIRIS (ravulizumab-cwvz) injection
Intravenous
Injection: 300 mg/30 mL (10 mg/mL) solution in a single-dose vial.
Injection: 300 mg/3 mL (100 mg/mL) solution in a single-dose vial.
Injection: 1,100 mg/11 mL (100 mg/mL) solution in a single-dose vial.
Subcutaneous
Injection: 245 mg/3.5 mL (70 mg/mL) solution in a single-dose prefilled
cartridge for use only with supplied single-use on-body injector.
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ ULTOMIRIS (ravulizumab-cwvz) injection ”. FDA approved ravulizumab-cwvz (brand name ULTOMIRIS) is not (yet) registered or available in India but on request Indian patient can buy ULTOMIRIS at the lowest price. Confirmation of the order for ULTOMIRIS (ravulizumab-cwvz) injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to FDA approved ravulizumab-cwvz (brand name ULTOMIRIS) India.
For personal use, get access to FDA approved ravulizumab-cwvz (brand name ULTOMIRIS) India. On request, We have imported and delivered Anti-cancer medicines to following cities in India – Ahmedabad, Bangalore, Surat, Kolkata, Pune, Indore, Nagpur, Agra, Kanpur, Patna, Coimbatore, Kochi, Delhi, Gurugram, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Bhopal, Mumbai, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Agartala, Lucknow, Dehradun, Gairsain. Aizawal, Aurangabad, Barshi, Cachar, Dibrugarh, Karungapally, Kollam, Meghalaya, Mizoram, Sikkim, Pondichery, Punjab, Tripura, New Delhi, Agra, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad.
ULTOMIRIS Sourcing & Delivery
Alleviare India specializes in sourcing and supplying ULTOMIRIS, a cancer treatment medicine, from around the world. They offer worldwide access to the best available treatment options. Alleviare India can dispense any valid prescription quickly and helps connect patients with potential distributors, wholesalers, suppliers, and dealers of ULTOMIRIS in India.
How much does ULTOMIRIS cost in the India?
Kindly reach out to us for ULTOMIRIS (ravulizumab-cwvz) injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
What documents are required to import ULTOMIRIS to India?
To import ravulizumab ULTOMIRIS, patients or government hospitals can place an order on behalf of the patients.
The following documentation is required for the import process:
- Valid prescription from a qualified doctor.
- Patients’ diagnostic reports.
- Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
- Valid prescription from the doctor.
- Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.
Is ULTOMIRIS available in India?
ULTOMIRIS ravulizumab is a prescription medication, which means it legally requires a medical prescription to be dispensed. Alleviare India assists in importing cancer medicines through the named patient supply (NPS) program. They provide information on the availability and prices of medications in various cities in India, such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune. Alleviare ensures 100% transparency and helps find genuine and reliable sources from Canada, Europe, USA, and Australia. They can facilitate the supply of ULTOMIRIS (prescription medicines) to locations worldwide, including India, while ensuring compliance with legal requirements.
Please contact or mail @ – info@alleviareindia.com +91 9289711087 / 9289711088 for ULTOMIRIS availability and prices in India. We guarantee the authenticity and quality of our products and offer worldwide delivery according to the buyer’s specifications.
Is ravulizumab available in India?
Yes, FDA approved ravulizumab-cwvz (brand name ULTOMIRIS) is not (yet) registered or available in India but on request Indian patient can buy ULTOMIRIS at the lowest price. Alleviare will help patient / doctor to get in India.
How overseas patient can get access?
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand ULTOMIRIS (ravulizumab-cwvz) injection. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to ULTOMIRIS (ravulizumab-cwvz) injection , they can inquire and find further information by sending their inquiries to ALS.
